title: Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy.
abstract: OBJECTIVE
  To evaluate the effect of an antiretroviral (ARV) therapy regimen containing zidovudine (AZT), lamivudine (3TC), and efavirenz (EFV) on the pharmacokinetics of depot medroxyprogesterone acetate (DMPA).
  
  
  METHODS
  Open-label, nonrandomized, clinical trial.
  
  
  METHODS
  University hospital clinic.
  
  
  METHODS
  Thirty HIV-infected women; 15 using ARV therapy (AZT, 3TC, and EFV) and 15 non-users of ARV therapy, followed biweekly for 12 weeks.
  
  
  METHODS
  Single injection of DMPA (150 mg IM) for both groups.
  
  
  METHODS
  Pharmacokinetic parameters of DMPA by liquid chromatography with mass spectrometry, and ovulation by serum P.
  
  
  RESULTS
  Maximum serum concentrations of DMPA were reached at 14 days after injection. The area under the curve was similar in both groups, as were the minimum concentration, half-life, and clearance. Only 1 woman, not using ARV therapy, ovulated at 11 weeks after DMPA.
  
  
  CONCLUSIONS
  Pharmacokinetics of DMPA were similar in HIV-infected women, regardless of ARV therapy use, suggesting that triple therapy with AZT, 3TC, and EFV is not likely to interfere with the contraceptive effectiveness of DMPA.
authors: Family Health International, Research Triangle Park, North Carolina 27709, USA. knanda@fhi.org
authors: Kavita
authors: K
authors: Nanda
authors: Eliana
authors: E
authors: Amaral
authors: Melissa
authors: M
authors: Hays
authors: Marco A M
authors: MA
authors: Viscola
authors: Neha
authors: N
authors: Mehta
authors: Luis
authors: L
authors: Bahamondes
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D003280:Contraceptives, Oral, Synthetic / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage* / Q000493:pharmacokinetics*
chemical_list: D044966:Anti-Retroviral Agents; D003280:Contraceptives, Oral, Synthetic; D003692:Delayed-Action Preparations; D017258:Medroxyprogesterone Acetate